TechNavio today launched its Global HIV Drugs Market 2010“2014 report based on an in-depth study focusing on the Americas and the EMEA and APAC regions. The report aids decision makers™ understanding of the key trends impacting the growth of this market.
Commenting on the report, an analyst from TechNavio™s Healthcare team said, Major issues such as resistance to ART, patent expirations, and increasing HIV infections have created a need for novel drugs. The trend is moving towards development of new ART drugs that operate outside infected cells. This could include new class of drugs for entry inhibitors, coreceptor antagonists and fusion inhibitors.
According to the report, early initiation of Highly Active AntiRetroviral Therapy (HAART) is the most effective way to reduce the risk of blood-borne infections. New studies from British Columbia Centre for Excellence (BC-CfE) in HIV/AIDS, San Francisco, states that HAART was associated with a 50 percent decrease in new yearly HIV infections among injection drug users. This driver is expected to have a huge impact on the market.
Key findings from the report:
¢ Increase in Prevalence of HIV Worldwide and Longer Life Expectancy of Patients
¢ Lack of Complete Cure and Length of Therapy
¢ Development of Immune-based therapies for HIV
The contents of this report are based on research conducted on an objective combination of primary and secondary scores, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit https://www.technavio.com/content/global-hiv-drugs-market-2010-2014
Follow us on Twitter @Technavio
TechNavio Announces the Publication of its Report “ Global HIV Drugs Market 2010“2014
